###begin article-title 0
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis
###end article-title 0
###begin title 1
Objective
###end title 1
###begin p 2
###xml 198 206 <span type="species:ncbi:9606">children</span>
The identification of novel autoantibodies in juvenile dermatomyositis (DM) may have etiologic and clinical implications. The aim of this study was to describe autoantibodies to a 140-kd protein in children recruited to the Juvenile DM National Registry and Repository for UK and Ireland.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 43 51 <span type="species:ncbi:9606">children</span>
###xml 426 434 <span type="species:ncbi:9606">children</span>
Clinical data and sera were collected from children with juvenile myositis. Sera that recognized a 140-kd protein by immunoprecipitation were identified. The identity of the p140 autoantigen was investigated by immunoprecipitation/immunodepletion, using commercial monoclonal antibodies to NXP-2, reference anti-p140, and anti-p155/140, the other autoantibody recently described in juvenile DM. DNA samples from 100 Caucasian children with myositis were genotyped for HLA class II haplotype associations and compared with those from 864 randomly selected UK Caucasian control subjects.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 586 587 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">children</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
###xml 741 749 <span type="species:ncbi:9606">children</span>
Sera from 37 (23%) of 162 patients with juvenile myositis were positive for anti-p140 autoantibodies, which were detected exclusively in patients with juvenile DM and not in patients with juvenile DM-overlap syndrome or control subjects. No anti-p140 antibody-positive patients were positive for other recognized autoantibodies. Immunodepletion suggested that the identity of p140 was consistent with NXP-2 (the previously identified MJ autoantigen). In children with anti-p140 antibodies, the association with calcinosis was significant compared with the rest of the cohort (corrected P < 0.005, odds ratio 7.0, 95% confidence interval 3.0-16.1). The clinical features of patients with anti-p140 autoantibodies were different from those of children with anti-p155/140 autoantibodies. The presence of HLA-DRB1*08 was a possible risk factor for anti-p140 autoantibody positivity.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
This study has established that anti-p140 autoantibodies represent a major autoantibody subset in juvenile DM. This specificity may identify a further immunogenetic and clinical phenotype within the juvenile myositis spectrum that includes an association with calcinosis.
###end p 8
###begin p 9
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 614 615 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 101 109 <span type="species:ncbi:9606">children</span>
###xml 157 165 <span type="species:ncbi:9606">children</span>
Juvenile dermatomyositis (DM) is the most common of the idiopathic inflammatory myopathies (IIMs) of children. The reported incidence is 0.8-4.1 per million children per year (1-3). Juvenile DM is chronic, potentially debilitating, and can be associated with significant morbidity. Due to the heterogeneity of the condition with multisystem disease, the clinical outcome (and thus prognosis) is difficult to predict. Certain clinical features, such as skin ulceration, calcinosis, gastrointestinal involvement, and respiratory disease, have been proposed as predictors of a severe disease course in juvenile DM (4-7).
###end p 9
###begin p 10
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
The precise etiology of IIMs is unknown, but there is increasing evidence to suggest an important role for autoimmunity. Knowledge of an autoantibody profile is an important cornerstone in the diagnosis of patients with a wide variety of autoimmune connective tissue disorders. Myositis-specific autoantibodies (MSAs) are being observed with increasing frequency in adult patients with IIM. There is now increasing evidence that MSAs are associated with homogeneous clinical subsets within the IIM spectrum, which can help predict clinical outcomes (8-10). For example, autoantibodies directed against the aminoacyl-transfer RNA synthetases (aaRS) form the largest group of MSAs in adult IIM and are associated with the antisynthetase syndrome (10,11). Other well-described MSAs in adult IIM that are associated with specific clinical manifestations include anti-signal recognition particle (anti-SRP) and anti-Mi-2 autoantibodies (10).
###end p 10
###begin p 11
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 861 869 <span type="species:ncbi:9606">patients</span>
To date, MSAs in juvenile myositis, including juvenile DM, have been less well characterized. Previous reports have described myositis-associated autoantibodies (MAAs), including anti-PM-Scl and anti-U1 RNP, in juvenile DM overlap syndromes (12). Anti-Mi-2 has been described more frequently, but this autoantibody specificity and others such as aaRS and anti-SRP are detected in a relatively small number of juvenile myositis cases (13-15). Recently, our group and other investigators have observed that autoantibodies to a 155-kd protein and a 155/140-kd doublet protein are a major serologic subset in juvenile DM (16,17). In addition, anti-p155/140 autoantibodies appear to define a distinct clinical phenotype within the juvenile DM spectrum (17). A further autoantibody termed anti-MJ, which targets a 140-kd protein, has been described in a US cohort of patients with juvenile DM (18). The MJ autoantigen was recently identified as nuclear matrix protein NXP-2 (19).
###end p 11
###begin p 12
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 143 151 <span type="species:ncbi:9606">children</span>
In this study, we describe the prevalence, clinical associations, and immunogenetic associations of autoantibodies targeting a p140 protein in children recruited to the Juvenile DM Registry and Repository for UK and Ireland (JDRR) (for review, see refs.6 and12). We demonstrate that anti-p140 and anti-p155/140 are different autoantibody subsets and investigate the identity of the p140 target, which is likely to be the same as the previously identified MJ autoantigen NXP-2 (also termed MORC3) (18,19).
###end p 12
###begin title 13
PATIENTS AND METHODS
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and sera
###end title 14
###begin p 15
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 1067 1075 <span type="species:ncbi:9606">children</span>
###xml 1155 1163 <span type="species:ncbi:9606">children</span>
The JDRR has recruited patients with juvenile-onset myositis, all of whom were younger than age 16 years at the time of disease onset and diagnosis, from 10 centers around the UK (6). All patients had probable or definite myositis according to the diagnostic criteria described by Bohan and Peter (20,21). Demographic and serial clinical data were recorded at the time of diagnosis and prospectively at subsequent visits (approximately every 6 months). The clinical information recorded comprised specific cutaneous manifestations, including the presence of Gottron's lesions, skin ulceration, edema, calcinosis, and the distribution of skin rash over the body. Details on muscle involvement included muscle enzymes (creatine kinase [CK] and lactate dehydrogenase [LDH]) and the Childhood Myositis Assessment Scale (CMAS) (22) at baseline. Data were stored onto a central database, using anonymous codes. Serum and DNA samples were obtained at the time of diagnosis and stored at -20degreesC until required. Serum samples for serologic typing were available from 162 children recruited to the registry. DNA for genotyping was available from 100 Caucasian children with juvenile DM.
###end p 15
###begin p 16
###xml 37 45 <span type="species:ncbi:9606">children</span>
###xml 402 410 <span type="species:ncbi:9606">children</span>
###xml 509 517 <span type="species:ncbi:9606">children</span>
###xml 652 660 <span type="species:ncbi:9606">children</span>
###xml 770 778 <span type="species:ncbi:9606">children</span>
Clinical data were available for 160 children, 74% of whom were female. The median age at disease onset was 6 years (interquartile range [IQR] 3-9 years), and the median age at the time of diagnosis was 7 years (IQR 4-10 years). For this study, the median followup period from disease onset to the time of data analysis was 48 months (IQR 33-72 months) for the overall cohort. One hundred thirty-seven children had juvenile DM. Juvenile DM-scleroderma (juvenile DM-SSc) overlap syndrome is well recognized in children with juvenile DM who have a history of Raynaud's phenomenon, sclerodactyly, and other sclerodermatous skin changes. In this study, 21 children were defined as having juvenile DM-SSc overlap syndrome, with 2 or more of the above-mentioned features. Two children were defined as having other forms of juvenile myositis, not specifically juvenile DM or juvenile DM-SSc overlap syndrome.
###end p 16
###begin p 17
###xml 210 218 <span type="species:ncbi:9606">children</span>
Sera from 124 juvenile disease control subjects (20 with scleroderma/linear scleroderma, 8 with systemic lupus erythematosus, and 96 with juvenile idiopathic arthritis) were also analyzed. No sera from healthy children were available, reflecting the ethical difficulties in studies of this nature. Therefore, sera from 50 healthy adult control subjects were also serotyped.
###end p 17
###begin title 18
Ethics approval
###end title 18
###begin p 19
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients or their parents gave fully informed written/parental consent to participate and provide biologic samples, according to the Declaration of Helsinki, under both national multicenter and local ethics committee regulations.
###end p 19
###begin title 20
Indirect immunofluorescence
###end title 20
###begin p 21
###xml 110 115 <span type="species:ncbi:9606">human</span>
Indirect immunofluorescence was performed by standard methods, using Hep-2 cells and fluorescein-labeled anti-human IgG (Sigma, Poole, UK).
###end p 21
###begin title 22
Protein immunoprecipitation (IP)
###end title 22
###begin p 23
###xml 167 168 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 192 193 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 327 329 325 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 490 491 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 515 516 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
IP with K562 cell extracts was performed as previously described (23). Briefly, 10 mul of sera was mixed with 2 mg protein A-Sepharose beads (Sigma) in IP buffer (10 mM Tris HCl, pH 8.0, 500 mM NaCl, 0.1% volume/volume Igepal) at room temperature for 30 minutes. Beads were washed in IP buffer prior to the addition of 120 mul 35S-methionine-labeled K562 cell extract. Samples were mixed at 4degreesC for 2 hours. Beads were washed in IP buffer followed by Tris buffered saline buffer (10 mM Tris HCl, pH 7.4, 150 mM NaCl) before being resuspended in 50 mul sodium dodecyl sulfate (SDS) sample buffer (Sigma). After heating, proteins were fractionated by 10% SDS-polyacrylamide gel electrophoresis, enhanced, fixed, and dried. Labeled proteins were analyzed by autoradiography.
###end p 23
###begin title 24
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
IP with mouse monoclonal anti-NXP-2 and immunodepletion experiments
###end title 24
###begin p 25
###xml 263 264 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 366 368 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 727 729 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Ten microliters of anti-p140-positive sera or 50 mul of commercial mouse antibody to NXP-2 (MORC3) (Medical and Biological Laboratories, Nagoya, Japan) was mixed with 100 mul of prewashed protein G Dynabeads (Dynal, Liverpool, UK) in sodium phosphate (pH 8.1, 0.1M) at room temperature for 30 minutes. The antigens were immunoprecipitated as described for IP, using 35S-methionine-labeled K562 cell extracts. Immunodepletion was performed to ascertain whether the IP pattern observed with anti-p140-positive juvenile DM sera and the commercial antibody to NXP-2 was attributable to precipitation of the same antigen. This method was also used to confirm that anti-p155/140-positive juvenile DM sera target a different protein (17). Cell extracts were depleted of autoantibody targets, using a reference anti-p140-positive juvenile DM serum, reference anti-p155/140-positive juvenile DM serum, and normal serum as a negative control.
###end p 25
###begin p 26
###xml 426 428 422 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Briefly, duplicate samples, each of which contained 10 mg protein A-Sepharose beads (when preparing predepleted p140 cell extract for IP with commercial anti-NXP-2, 150 mul prewashed protein G Dynabeads was used) in 1 ml IP buffer and 50 mul anti-p140 serum (or 50 mul anti-p155/140 serum) were mixed at room temperature for 30 minutes. The beads were washed in IP buffer, and 1 tube (tube A) was placed on ice, while 120 mul 35S-methionine-labeled K562 cell extract and 380 mul IP buffer were added to tube B. Tube B was mixed at 4degreesC for 2 hours; the supernatant was transferred to the corresponding tube A, which was then mixed at 4degreesC for an additional 2 hours. The supernatant from the corresponding tube A (i.e., p140 antigen-depleted cell extract or p155/140 antigen-depleted cell extract) was stored at -80degreesC. IP with depleted cell extracts was completed using 50 mul commercial anti-NXP-2, different anti-p140 sera (10 mul), or different anti-p155/140 sera (10 mul).
###end p 26
###begin title 27
HLA typing
###end title 27
###begin p 28
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 143 151 <span type="species:ncbi:9606">Patients</span>
DNA samples from Caucasian patients with juvenile DM were extracted from blood samples and analyzed using a standard phenol-chloroform method. Patients were broad-typed for the HLA-DRB1 and DQB1 loci using a commercially available polymerase chain reaction sequence-specific oligonucleotide probe typing system (Dynal, Hamburg, Germany), as previously described (24). The HLA-DQA1 data were derived from the DRB1 and DQB1 results, using well-documented Caucasian haplotype tables (25).
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 289 290 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 394 395 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 620 622 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
Clinical and HLA allelic associations were derived from 2 x 2 contingency tables, using the chi-square test or 2-tailed Fisher's exact test when the value for individual cells was </=5. Significant results were expressed as odds ratios (ORs) with exact 95% confidence intervals (95% CIs). P values were adjusted using the Bonferroni correction when comparing clinical associations. Uncorrected P values are presented for possible immunogenetic associations. Haplotypes were estimated for selected loci using the expectation-maximization algorithm, as implemented in HelixTree (version 3.1.2; Golden Helix, Bozeman, MT) (22). SPSS for Windows (version 14; SPSS, Chicago, IL) (for clinical data) and Stata (release 9; Stata Corp., College Station, TX) (for HLA data) were used to perform statistical analysis.
###end p 30
###begin title 31
RESULTS
###end title 31
###begin title 32
Identification of anti-p140 autoantibodies in juvenile DM sera
###end title 32
###begin p 33
###xml 141 149 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Following IP, sera from several patients with juvenile DM recognized a distinct protein band with a molecular weight of approximately140 kd (Figure 1). No anti-p140-positive sera were observed to immunoprecipitate any other known MSAs or MAAs. A weak nonspecific nuclear pattern (or, in some cases, antinuclear antibody negativity) was observed by indirect immunofluorescence in all anti-p140 sera (data not shown). Anti-p140 was not detected in any of the juvenile disease control sera or healthy adult control sera.
###end p 33
###begin p 34
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Immunoprecipitation of p140 autoantigens. The autoradiogram shows the results of 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis of immunoprecipitates of 35S-methionine-labeled K562 cell extracts, using normal serum (lane 1), anti-p155/140-positive juvenile dermatomyositis (DM) serum (lane 2), and different anti-p140-positive juvenile DM sera (lanes 3-14).
###end p 34
###begin title 35
Confirmation of the p140 autoantigen
###end title 35
###begin p 36
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 334 342 334 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 683 691 683 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
###xml 1044 1052 1044 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
Our results suggest that the p140 protein targeted by juvenile DM sera in our study has the same identity as the MJ antigen, NXP-2 (19). Using a commercial antibody raised against NXP-2, IP resulted in the precipitation of a band with the same molecular weight and IP pattern as those observed in anti-p140-positive juvenile DM sera (Figure 2, lane 3). When the cell extract was predepleted with juvenile DM anti-p140-positive sera, the IP band present with commercial anti-NXP-2 was no longer detectable (Figure 2, lane 4). The immunodepletion results support the co-identity of the p140 protein precipitated by different anti-p140-positive juvenile sera (complete data not shown). Figure 3 (lanes 5 and 6) shows an example in which the 140-kd band is no longer detectable following IP with anti-p140 sera (designated "1") and using predepleted reference p140 cell extract (designated "2"). In addition, immunodepletion confirmed that anti-p140 sera target a different protein to juvenile DM sera that recognizes the p155/140 doublet protein (Figure 3, lanes 1-4, showing that the respective bands are still present following IP).
###end p 36
###begin p 37
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 418 420 418 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Immunodepletion of commercial NXP-2. The autoradiogram shows the results of 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis of immunoprecipitates of 35S-labeled K562 cell extracts using normal sera (NS; lane 1), reference anti-p140-positive juvenile dermatomyositis (DM) serum (lane 2), and commercial anti-NXP-2 (lane 3). Lane 4 shows the results of immunoprecipitation using commercial anti-NXP-2 with 35S-methionine-labeled cell extract predepleted with reference anti-p140-positive juvenile DM serum. IPP = immunoprecipitation.
###end p 37
###begin p 38
###xml 361 363 361 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 533 541 533 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
Immunodepletion experiments with anti-p140 and anti-p155/140. The autoradiogram shows the results of 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis of immunoprecipitates, using different anti-p140-positive juvenile DM sera (lanes 1, 2, 5, and 6) and anti-p155/140-positive juvenile DM sera (lanes 3 and 4). Immunoprecipitation was performed with 35S-methionine-labeled K562 cell extracts predepleted with either reference anti-p140-positive juvenile DM serum or reference anti-p155/140-positive juvenile DM serum. See Figure 2 for definitions.
###end p 38
###begin title 39
Clinical associations of anti-p140 autoantibodies
###end title 39
###begin p 40
###xml 439 446 439 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 943 944 943 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 946 947 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 947 951 947 951 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 1102 1103 1102 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1103 1107 1103 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 854 862 <span type="species:ncbi:9606">children</span>
###xml 923 931 <span type="species:ncbi:9606">children</span>
###xml 1245 1253 <span type="species:ncbi:9606">patients</span>
###xml 1277 1285 <span type="species:ncbi:9606">patients</span>
Of 162 juvenile myositis sera serotyped by IP, 37 (23%) had anti-p140 autoantibodies. This autoantibody specificity was observed exclusively in sera from patients with juvenile DM, with a frequency of 27%. Anti-p140 was not detected in any sera from patients with juvenile DM-SSc overlap syndrome. Selected clinical features of anti-p140-positive patients compared with the overall anti-p140-negative juvenile myositis cohort are shown in Table 1. There was no significant difference in the female-to-male ratio, the age at the time of disease onset or diagnosis, and disease duration (from disease onset to the time of this study) between anti-p140-positive and anti-p140-negative patients. Overall, there was no significant difference in the presence of Gottron's lesions, skin ulceration, edema, or the distribution of rash, except anti-p140-positive children had no rashes on the trunk compared with anti-p140-negative children (corrected P [Pcorr] = 0.02). Anti-p140-positive cases were significantly associated with the presence of subcutaneous calcinosis compared with anti-p140-negative cases (Pcorr < 0.005, OR 7.0, 95% CI 3.0-16.1). There was no significant difference between other clinical features when comparing anti-p140-positive patients and anti-p140-negative patients, including the baseline CK level, the CMAS score, the Childhood Health Assessment Questionnaire (C-HAQ) score (26), the physician's global assessment scale (PGA) score, and the presence of arthritis, Raynaud's phenomenon, dysphagia, mouth ulcers, and alopecia (data not shown).
###end p 40
###begin p 41
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="tf1-1">*</xref>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Selected clinical features of anti-p140-positive patients with juvenile DM compared with anti-p140-negative juvenile DM patients with myositis and anti-p155/140-positive juvenile DM patients*
###end p 41
###begin p 42
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Except where indicated otherwise, values are the percent of patients. DM = dermatomyositis; IQR = interquartile range.
###end p 42
###begin p 43
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Not all patients had clinical data available for each feature.
###end p 43
###begin p 44
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 14 18 14 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 132 133 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 133 137 133 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
Corrected P (Pcorr) < 0.005, odds ratio (OR) 7.0, 95% confidence interval (95% CI) 3.0-16.1 versus anti-p140-negative patients, and Pcorr = 0.015, OR 7.1, 95% CI 2-25 versus anti-p155/140-positive patients.
###end p 44
###begin p 45
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Pcorr = 0.05, OR 13.5, 95% CI 2-113 versus anti-p155/140-positive patients.
###end p 45
###begin p 46
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 54 58 54 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Pcorr = 0.02 versus anti-p140-negative patients, and Pcorr < 0.005 versus anti-p155/140-positive patients.
###end p 46
###begin p 47
###xml 126 133 126 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 510 511 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 511 515 511 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 827 828 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 828 832 828 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 870 874 870 874 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">corr</sub>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
###xml 933 941 <span type="species:ncbi:9606">children</span>
###xml 975 983 <span type="species:ncbi:9606">patients</span>
Possible clinical differences were noted when anti-p140-positive patients were compared with anti-p155/140-positive patients (Table 1). Overall, the age at disease onset or diagnosis and disease duration (for anti-p140-positive patients, median 48 months [IQR 34-72]; for anti-p155/140-positive patients, median 52 months [IQR 36-84]) were similar between the 2 autoantibody groups. Compared with anti-p155/140-positive patients, anti-p140-positive patients had an association with calcinosis (14% versus 54%; Pcorr = 0.015, OR 7.1 [95% CI 2-25]). In contrast, anti-p155/140-positive patients compared with the anti-p140-positive group had a higher frequency of ulceration and cutaneous edema; however, this result was not significant after correcting for multiple comparisons. The distribution of rash was wider on the trunk (Pcorr < 0.005) and over the small joints (Pcorr = 0.05, OR 13.5 [95% CI 2-113]) in anti-p155/140-positive children compared with anti-p140-positive patients.
###end p 47
###begin p 48
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 82 90 <span type="species:ncbi:9606">children</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
At the time of diagnosis, anti-p140-positive compared with anti-p155/140-positive children had a nonsignificantly lower CK level (median 202 IU/liter [IQR 76-2,142] versus median 571 IU/liter [IQR 234-2,495]) and LDH level (median 845 IU/liter [IQR 710-1,620] versus median 1,171 IU/liter [IQR 736-1,647]). In addition, anti-p140-positive patients had a higher CMAS score at the time of diagnosis compared with anti-p155/140-positive patients (median 42 [IQR 23-49] versus median 16 [IQR 7-38]; P not significant after adjustment for multiple comparisons). There was a nonsignificant trend toward a lower baseline C-HAQ score and PGA score in the anti-p140 group compared with the anti-p155/140 group (median C-HAQ score 1.31 [IQR 0.75-1.63] versus median 1.63 [IQR 0.78-2.34]); median PGA score 5 [IQR 3-7.4] versus median 7.3 [IQR 5-7.8]). However, these results need to be interpreted in the context that these data were recorded for only a small number of patients at the time of diagnosis.
###end p 48
###begin title 49
Immunogenetic associations of anti-p140 autoantibodies
###end title 49
###begin p 50
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
HLA-DRB1*08 was a possible immunogenetic risk factor and was present in 23.5% of 17 anti-p140-positive patients compared with 5.4% of 864 control subjects (P = 0.01, OR 5.3 [95% CI 1.2-18.1]). HLA-DRB1*08 was observed in 4.8% of 83 anti-p140-negative patients and in 11.8% of 18 anti-p155/140-positive patients. DQA1*06 was also observed more frequently in anti-p140-positive patients (11.8% of 17 patients compared with 1% of 192 control subjects; P = 0.03, OR 12.7 [95% CI 0.8-181.0]). This haplotype was not observed in anti-p140-negative or anti-p155/140-positive patients. However, these results were not significant after correcting for multiple comparisons.
###end p 50
###begin title 51
DISCUSSION
###end title 51
###begin p 52
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 1088 1090 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1091 1093 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 928 936 <span type="species:ncbi:9606">patients</span>
There is now increasing evidence that MSAs are associated with (and thus can identify) clinical subsets within the adult IIM spectrum. Our study suggests that specific genetic and serologic profiles may also be associated with clinical phenotypes in juvenile DM (12-17). In this report, we describe the novel autoantibody specificity, anti-p140, in a UK cohort study of patients with juvenile DM. The presence of anti-p140 autoantibodies represents a major serologic subset in juvenile myositis; it was observed exclusively in juvenile DM and was not detected in any cases of juvenile DM-SSc overlap syndrome. All anti-p140-positive sera recognized the same polypeptide and did not immunoprecipitate any other known myositis autoantigens, including the anti-p155/140 autoantibody (16,17). Combining the data from our UK juvenile DM cohort studies, anti-p140 and anti-p155/140 autoantibodies were detected in approximately40% of patients with juvenile DM, in contrast to a much lower frequency of anti-Mi-2 and other myositis-specific or associated autoantibodies, as previously reported (12-15).
###end p 52
###begin p 53
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
The confirmation of a further serologic subset in juvenile DM appears to have important clinical implications. Anti-p140 positivity was significantly associated with the presence of calcinosis when compared with the overall juvenile myositis cohort. In addition, anti-p140 and anti-p155/140 appear to define juvenile DM into 2 serologic subsets with more homogeneous clinical features. The results of this study, combined with our previous work (17), suggest that anti-p155/140-positive patients have a wider distribution of skin disease, more cutaneous complications including edema or ulceration, and possibly overall higher disease activity but a significantly lower frequency of calcinosis compared with anti-p140-positive patients.
###end p 53
###begin p 54
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">children</span>
The clinical differences observed between anti-p140-positive patients, anti-p155/140-positive patients, and patients with neither of these specificities are not explained by differences in the time to disease onset or disease duration. This is an interesting observation, because a factor suggested to influence the development of calcinosis is persistent active disease, including chronic cutaneous inflammation (27-29). The association between serotype and clinical phenotype suggests that the targeted autoantigens p140 and p155/140 may play a role in the pathogenesis of skin and soft tissue complications in juvenile DM. In addition, HLA-DRB1*08 is a possible immunogenetic risk factor for the development of anti-p140 autoantibodies in Caucasian children with juvenile DM.
###end p 54
###begin p 55
###xml 161 163 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
Based on previous work that showed an association with the tumor necrosis factor alpha (TNFalpha) 308A allele, increased production of TNFalpha, and calcinosis (28), future studies to investigate for other potential susceptibility genes, including TNF polymorphisms, in juvenile DM patients with anti-p140 or anti-p155/140 autoantibodies would be of major interest.
###end p 55
###begin p 56
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 479 487 <span type="species:ncbi:9606">children</span>
The p140 protein targeted by an autoimmune response in our juvenile DM cohort study is consistent with NXP-2, the MJ autoantigen described in preliminary reports in a US juvenile DM cohort (18,19). NXP-2 has nuclear matrix-binding, RNA-binding, and coiled-coil domains that are structurally separated, which may implicate a role in diverse nuclear functions including regulation of transcriptional and RNA metabolism (30). Previously described DM-specific autoantigen targets in children and adults, Mi-2 and p155/140 (p155; transcription intermediary factor 1 gamma) (31,32), are nuclear proteins that also mediate gene transcription. It is of further interest to note that autoantibodies to small ubiquitin-like modifier activating enzyme (SAE), which is involved in posttranscriptional modification termed sumoylation, have been described in adult DM (33). To date, anti-SAE autoantibodies have not been detected in juvenile myositis sera (Gunawardena H: unpublished observations). However, NXP-2 has been shown to be a sumoylation target involved in transcriptional repression (34), which may suggest potential shared pathogenic mechanisms in both juvenile and adult DM.
###end p 56
###begin p 57
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 418 426 <span type="species:ncbi:9606">children</span>
In conclusion, anti-p140 autoantibody is a clinically important serologic marker that is observed with a high frequency in patients with juvenile DM and is associated with calcinosis, a complication of the disease that confers significant morbidity. In the future, routine testing for these novel autoantibodies (anti-p140 and anti-p155/140) at the time of disease onset could have prognostic value and identify those children who are at risk of more severe disease, which may influence management. Furthermore, increasing our understanding of autoimmune targets and their relationship to the clinical phenotype in juvenile myositis may provide further insight into pathogenic pathways that in turn will stimulate new therapeutic approaches.
###end p 57
###begin title 58
AUTHOR CONTRIBUTIONS
###end title 58
###begin p 59
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Prof. McHugh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
###end p 59
###begin p 60
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Study conception and design.</bold>
Study conception and design. Gunawardena, Wedderburn, Chinoy, Betteridge, North, Cooper, Davidson, McHugh.
###end p 60
###begin p 61
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acquisition of data.</bold>
Acquisition of data. Gunawardena, Wedderburn, Chinoy, Betteridge, North, Cooper, Davidson, McHugh.
###end p 61
###begin p 62
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Analysis and interpretation of data.</bold>
Analysis and interpretation of data. Gunawardena, Wedderburn, Chinoy, Betteridge, North, Ollier, Cooper, Oddis, Ramanan, Davidson, McHugh.
###end p 62
###begin p 63
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supervision of sample and data collection.</bold>
Supervision of sample and data collection. Wedderburn.
###end p 63
###begin p 64
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">Children</span>
###xml 408 416 <span type="species:ncbi:9606">Children</span>
###xml 473 481 <span type="species:ncbi:9606">Children</span>
###xml 560 568 <span type="species:ncbi:9606">Children</span>
###xml 643 651 <span type="species:ncbi:9606">Children</span>
###xml 826 834 <span type="species:ncbi:9606">Children</span>
###xml 868 873 <span type="species:ncbi:8895">Swift</span>
###xml 1764 1772 <span type="species:ncbi:9606">patients</span>
The Juvenile Dermatomyositis Research Group would like to thank all of the patients and their families who contributed to the Juvenile Dermatomyositis Cohort Study. We thank all local research coordinators and principal investigators who have made this research possible. The members who contributed were as follows: Ian Roberts (The Royal Liverpool Children's Hospital, Alder Hey, Liverpool, and Booth Hall Children's Hospital, Manchester), Dr. Eileen Baildam (Booth Hall Children's Hospital, Manchester, and Alder Hey, Liverpool), Dr. Phil Riley (Booth Hall Children's Hospital, Manchester), Mrs. Janis Scott and Dr. Clive Ryder (Birmingham Children's Hospital, Birmingham), Mrs. Gillian Jackson and Dr. Sue Wyatt (Leeds General Infirmary, Leeds), Ms Elizabeth Camp and Dr. Janet Gardner-Medwin (The Royal Hospital for Sick Children, Yorkhill, Glasgow), Mrs. Alison Swift, Dr. Helen Foster, and Dr. Mark Friswell (The Royal Victoria Infirmary, Newcastle), Mrs. Elizabeth Hutchinson and Dr. Helen Venning (Queens Medical Centre, Nottingham), and Dr. Clarissa Pilkington, Dr. N. Hasson, and Ms Sue Maillard (Great Ormond Street Hospital, London). In addition, we would like to thank the Childhood Arthritis Prospective Study (CAPS) group for allowing us access to juvenile arthritis plasma samples. The members who contributed to CAPS are as follows: Wendy Thomson, Kimme Hyrich, Mark Lay, Sham Lal, Paul Gilbert, Peter Ward (ARC); Eileen Baildam, Carol Lydon, Lynsey Brown (Alder Hey); Joyce Davidson, Janet Gardner-Medwin, Vicki Price, Jane Sim, Maureen Todd (Glasgow); Lucy Wedderburn, Alexandra Meijer, Julie Jones (Great Ormond Street); Helen Foster, Mark Friswell, Michael Eltringham (Newcastle); Alice Chieng, Joanne Buckley (Manchester). We also thank the patients and their families who contributed to CAPS. Finally, we are grateful to H. Varsani for technical assistance.
###end p 64
###begin title 65
REFERENCES
###end title 65
###begin article-title 66
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry
###end article-title 66
###begin article-title 67
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982
###end article-title 67
###begin article-title 68
The incidence of juvenile dermatomyositis: results from a nation-wide study
###end article-title 68
###begin article-title 69
###xml 69 77 <span type="species:ncbi:9606">children</span>
Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis
###end article-title 69
###begin article-title 70
Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes
###end article-title 70
###begin article-title 71
###xml 108 116 <span type="species:ncbi:9606">children</span>
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr
###end article-title 71
###begin article-title 72
Paediatric idiopathic inflammatory muscle disease: recognition and management
###end article-title 72
###begin article-title 73
###xml 133 140 <span type="species:ncbi:9606">patient</span>
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups
###end article-title 73
###begin article-title 74
Update on myositis-specific and myositis-associated autoantibodies
###end article-title 74
###begin article-title 75
Myositis specific autoantibodies
###end article-title 75
###begin article-title 76
Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies
###end article-title 76
###begin article-title 77
###xml 56 64 <span type="species:ncbi:9606">children</span>
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap
###end article-title 77
###begin article-title 78
Clinical significance of specific autoantibodies in juvenile dermatomyositis
###end article-title 78
###begin article-title 79
###xml 79 87 <span type="species:ncbi:9606">children</span>
A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children
###end article-title 79
###begin article-title 80
###xml 64 69 <span type="species:ncbi:9606">girls</span>
Autoantibody to signal recognition particle in African American girls with juvenile polymyositis
###end article-title 80
###begin article-title 81
A novel autoantibody to a 155-kd protein is associated with dermatomyositis
###end article-title 81
###begin article-title 82
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis
###end article-title 82
###begin article-title 83
Clinical and serological characterization of the anti-MJ antibody in childhood myositis
###end article-title 83
###begin article-title 84
Sera with autoantibodies to the MJ antigen react with NXP2
###end article-title 84
###begin article-title 85
Polymyositis and dermatomyositis (first of two parts)
###end article-title 85
###begin article-title 86
Polymyositis and dermatomyositis (second of two parts)
###end article-title 86
###begin article-title 87
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function
###end article-title 87
###begin article-title 88
Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia
###end article-title 88
###begin article-title 89
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
###end article-title 89
###begin article-title 90
HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids
###end article-title 90
###begin article-title 91
###xml 32 40 <span type="species:ncbi:9606">children</span>
Measurement of health status in children with juvenile rheumatoid arthritis
###end article-title 91
###begin article-title 92
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis
###end article-title 92
###begin article-title 93
TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications
###end article-title 93
###begin article-title 94
###xml 33 41 <span type="species:ncbi:9606">children</span>
Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation
###end article-title 94
###begin article-title 95
###xml 21 26 <span type="species:ncbi:9606">human</span>
The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains
###end article-title 95
###begin article-title 96
Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis
###end article-title 96
###begin article-title 97
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene
###end article-title 97
###begin article-title 98
Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis
###end article-title 98
###begin article-title 99
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression
###end article-title 99

